DJIA 17,195.42 221.11 1.30%
NASDAQ 4,566.14 16.91 0.37%
S&P 500 1,994.65 12.35 0.62%
market minute promo

OXIGENE, INC. (NASDAQ: OXGN)

2.36 -0.02 (-0.84%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

OXGN $2.36 -0.84%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.38
Previous Close $2.38
Daily Range $2.30 - $2.40
52-Week Range $1.75 - $5.40
Market Cap $48.9M
P/E Ratio -1.04
Dividend (Yield) $0.00 (0.0%)
Volume 782,690
Average Daily Volume 569,264
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

OXIGENE, INC. (OXGN) Description

A biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. Website: http://www.oxigene.com/

News & Commentary Rss Feed

Inhibitex Investors: Why Shares Popped 115%

Great results for INX-189 send shares skyward.

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

3 Biotech Stocks Under $10 in Breakout Territory

OXiGENE Announces First Patient Enrolled In Phase 1b/2 Study of Fosbretabulin Combined With Pazopani

OXiGENE Announces First Patient Enrolled In Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer

OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting o

OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society

Update: OXiGENE Initiates Clinical Trial -- Shares Rise

OXiGENE Reports Commencement of Phase 2 Study of Fosbretabulin

Update: OXiGENE Earnings - Q2 Miss Challenges My Patience

OXiGENE's (OXGN) CEO David Chaplin on Q2 2014 Results - Earnings Call Transcript

OXiGENE (OXGN) Q2 2014 Results - Earnings Call Webcast

Update: CEO Departure And Recent Capital Raise At OXiGENE Reaffirms Bull Thesis

See More OXGN News...

OXGN's Top Competitors

OXGN $2.36 (-0.84%)
Current stock: OXGN
AMGN $161.58 (1.70%)
Current stock: AMGN
GILD $114.22 (3.16%)
Current stock: GILD
BIIB $321.00 (1.89%)
Current stock: BIIB